Novartis Owns the Migraine Market...we are done.

Aimovig approved months ahead of ours. Does anyone really think we have a shot in this market? You realize how many patients will already be on Aimovig when ( and if ) we actually make it to market. I heard Teva is selling it, and are throwing in the towel on the branded side by the end of the year.

 

Not good news. I think we are delayed longer then they want to tell us and we are done.

 

If we ever make it to market we will be #3 or #4. We are delayed a lot longer than expected. This isn’t simple a pgarmaceutical compound it’s a monoclonal. We are toast!

 

Stop whining like a bunch of pussies.
It’s a whole new market. You really think just because Amgen is a few months ahead that no hcps will have any interest in the others (ours included) that will be hitting the market?
Get real. It’s a huge market, and docs are ready to write. Insurance companies are going to wait and see before prioritizing coverage. It’s a great time to be here.
All these meds are needed and will have a solid shot.
If you really are part of our company, which in all likelihood you aren’t, stop coming on here bitching because we’ll be a few months behind in a totallly new market of meds.

You sound like an asshole.

 

You’re mom is toast.

You sound like an asshole.

 

All of this depends on how long the drug is delayed. If it is delayed into next year, it will not make it. There will be some prescriptions but not what is needed to make it successful.

 

Wow, drink some more kool aid. It all depends on how long we are delayed. It probably won't be just a few months that Amgen is ahead of us. Plus our managed care sucks in every launch.

 

MC contracts are being delivered now for 2019. If it gets approved during the last part of this year or next year we will not have MC coverage in 2019 and our competitors will have coverage.

 

You think that formularies are making decisions now on a brand new class of drugs with the first one being available this week? You think there will be any “coverage” for the first 3-6 months? Think it through!

 

I said they will present contracts to MC to contract in 2019. We will see if and how much coverage is agreed upon. But we know first approved has the best shot with second and third class approval, will make it a more competitive landscape.

 

This is hilarious; I’d be bitter too for selling an MS drug than having to choose to ditch it or go into migraine as you have Troll. Keep posting here pretending to know anything about our drug which will absolutely destroy yours and bring over patients just like we’ve done in the MS space with your horsesh** drug. Oh and hope you’re “non-branded” programs went off great as all of our docs have said they were completely pointless.

 

The person you call “troll” makes
The valid and key point that it is a BIG deal to be first for market with a novel compound in this type of specific market. Physicians will try the first one— often in their most difficult to treat patients—
Who can have robust responses. Doctor then has a very positive opinion of drug if it “works” and benchmarks all that follow to it. Teva owns that the delay is not
A good thing, so not sure why the childish name calling and talk of
Horse waste.

 

This thread is hysterical. Have you ever seen Teva do something well. I mean yes 20 years ago Copaxone was great but that was 20 years ago and Teva hasn’t done anything remarkable since. Everyone is leaving or looking, we will be second to market, our teams have no excitement anymore and everyone is either scaping the barrel for an MS patient or struggling to find one more HD patient. I’m outta here! Teva used to be a great place but I think we have reached the end of the yellow brick road paved with Copaxone.

 

Bye Felicia

 

Then move on looser and don't let the door hit you in the ASS. You will be posting again in a year or two, saying the same old crap about your next company. See if the grass is any greener wherever you decide to go.

 

Grass IS greener...a lot greener!

 

Doomed?? Doubtful.... they are getting years and years of Warehouse patients though the statistics said over 10,000 prescriptions already

 

NVS and Amgen also own the record for F'ed up launches. And very few at either co will argue that. Major problems w/ HUB so far, which is par for Specialty drugs.

 

Amgen grossly underestimated demand. Hub is swamped. As of 6/6 they are averaging 1200 rx day with 72% of neuros with at least 1 rx.
(Wife is a sec for a amg big wig)